Dendreon Corporation DNDN today announced that the U.S. Food and Drug Administration approved its Atlanta cancer immunotherapy manufacturing facility, the third location at which the Company will produce PROVENGE® to help meet the needs of patients across the U.S. with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
The Atlanta facility includes 36 workstations, and Dendreon will bring these new workstations online in a staged approach. With this FDA approval and the approved New Jersey and Los Angeles facilities, Dendreon now has three facilities available to manufacture PROVENGE.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in